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Although FoxP3þ regulatory T cells are key players in the maintenance of immune tolerance and auto-
immunity, the lack of speciﬁc markers constitute an obstacle to their use for immunotherapy protocols.
In this study, we have investigated the role of the C-type lectin receptor CD69 in the suppressor function
of Tregs and maintenance of immune tolerance towards harmless inhaled antigens. We identiﬁed a novel
FoxP3þCD69þ Treg subset capable to maintain immune tolerance and protect to developing inﬂamma-
tion. Although CD69þ and CD69FoxP3þ Tregs exist in homeostasis, only CD69-expressing Tregs express
high levels of CTLA-4, ICOS, CD38 and GITR suppression-associated markers, secrete high amounts of
TGFb and have potent suppressor activity. This activity is regulated by STAT5 and ERK signaling pathways
and is impaired by antibody-mediated down-regulation of CD69 expression. Moreover, immunotherapy
with FoxP3þCD69þ Tregs restores the homeostasis in Cd69/ mice, that fail to induce tolerance, and is
also highly proﬁcient in the prevention of inﬂammation. The identiﬁcation of the FoxP3þCD69þ Treg
subset paves the way toward the development of new therapeutic strategies to control immune ho-
meostasis and autoimmunity.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
FoxP3þ regulatory T (Treg) cells are a subset of CD4þ T lym-
phocytes with suppressive activity, key mediator of peripheral
tolerance and essential for preventing autoimmune and chronic
inﬂammatory diseases. However, the lack of speciﬁc markers and
insufﬁcient understanding of Tregs biology constitute the two
largest obstacles to develop immunotherapy protocols for the
treatment of these diseases [1]. Treg cells inhibit proliferation and
function of effector T cells through various mechanisms, including
cellecell contact and the production of anti-inﬂammatory cyto-
kines such as TGF-b or IL-10. Tregs can develop in the thymus, or
from naïve CD4þ Tcells in the periphery [2]. After antigen challengeBiology and Inﬂammation,
s Carlos III (CNIC), Melchor
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Tregs, which upregulate speciﬁc adhesion and chemokine receptors
and migrate to the inﬂamed tissue. This regulatory mechanism of
cell migration is critical for a proper balance between the innate
and adaptive immune responses in the inﬂamed tissue [3]. In this
regard, S1P1 has been described as an important molecule con-
trolling lymphocyte egress from lymphoid organs and leukocyte
receptor CD69 negatively regulates its expression [4].
The early leukocyte activation antigen CD69 is a membrane
receptor from the family of type II C-type lectins. CD69 is rapidly
induced after cell activation in all bonemarrow derived cells except
erythrocytes [5,6]. Expression of CD69 in vivo is restricted to posi-
tively selected thymocytes and leukocytes undergoing activation,
particularly at inﬂammatory sites. Engagement of CD69 with
monoclonal antibodies (mAbs) in the presence of phorbol esters
induces a strong Ca2þ inﬂux leading to the activation of ERK, in-
duction of IL-2 and IFN-g genes, and T cell proliferation [7,8].
However, in vivo studies with CD69-deﬁcient mice revealed an
unexpected immunoregulatory role [9]. A mouse model of
lymphocyte-dependent collagen-induced arthritis (CIA) suggested
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levels at the site of inﬂammation [10]. Since TGF-b participates in
the differentiation both of regulatory T cells and of Th17 cells
[11,12], CD69 might regulate the immune response at the stage of T
cell differentiation. The balance between Th17 and Treg cells is
critical for the regulation of the immune response by determining
the net balance of pro- and anti-inﬂammatory cytokines at the
inﬂammatory foci.
In this report we have analyzed the role of CD69 in the function
of FoxP3þ Tregs. We show that around half of the Tregs located in
lymphoid organs express CD69 in steady state. CD69þ Tregs express
higher surface levels of suppression-associated markers than
CD69 Tregs cells or Tregs from Cd69/ mice, and have enhanced
suppressor activity in vitro and in a mouse model of lung tolerance
to harmless antigens. Our results strongly support a role for CD69 as
a critical receptor for controlling Treg-suppressor function in both
physiological and pathological immune responses, including
autoimmunity and allergy.
2. Materials and methods
2.1. Animals
CD69-deﬁcient mice were generated as described [13]. C57BL/
6 Tg(TcraTcrb)425Cbn/J mice expressing a T-cell receptor speciﬁc
for peptide 323e339 of OVA in the context of I-Ab (OTII mice) were
purchased from the Jackson Laboratory (stock number 004194).
OTII micewere backcrossedwith CD69-deﬁcientmice in the C57BL/
6 background (OTKO mice). For in vivo tolerogenic asthma experi-
ments, we used females 10e12 weeks old that were either litter-
mates or age-matched offspring in BALB/c or OTII background.
Foxp3-RFP reported mice were kindly provided by Dr. R.A. Flavell
(Yale University). Mice were kept in SPF conditions at the Animal
Facility of CNIC. Experimental procedures were approved by the
CNIC Committee for Research Ethics and conducted under Animal
Welfare and Health Spanish and European guidelines.
2.2. T-cell isolation
Single-cell suspensions were obtained from spleen or mesen-
teric lymph nodes and incubated with the following biotinylated
antibodies: CD8, CD19, B220, MHCII, CD11c, IgM, DX5 and CD11b,
followed by streptavidin Microbeads. CD4þ T cells were negatively
selected with auto-MACS Pro (Miltenyi) separator. The negative
fraction was incubated with anti-CD25 biotin to obtain Tregs.
2.3. Treg cell suppression assays
Tconvs were cultured with coated a-CD3 antibody (1 mg/mL)
plus indicated amounts of soluble a-CD28 or irradiated T cellede-
pleted splenocytes. For antigen-speciﬁc assays, CD4þ T cells from
OTII and OTKOmicewere cultured in the presence of irradiated APC
and OVAp (10 mg/mL). T cell proliferation was measured by [3H]-
thymidine incorporation for the last 16 h of culture or by CFSE or
CellTraceViolet staining of CD4þ Tconv cells.
2.4. Intracellular staining and FACS
Tregs or Tconv cells were treated with 1 mg/ml anti-CD3 (145-
2C11) and anti-CD28 (37.51), and crosslinked with antieArmenian
Hamster IgG F(ab')2 (20 mg/mL). Activationwas arrested by ﬁxation
with 4% formaldehyde and permeabilized with 90% methanol and
cells were incubated with phospho-Akt, phospho-Erk and
phospho-Stat5 from Cell Signaling.2.5. In vitro differentiation of Tregs
OVA-speciﬁc TCR transgenic naïve T cells were obtained from
OTII and OTKO mice and cultured for 72 h with irradiated APCs in
the presence of 10 mg/ml OVAp, recombinant TGF-b1, and IL-2.
In vitro differentiation of iTregs from C57BL/6 mice with normal
TCR was performed from naïve CD4 T cells from CD69-proﬁcient or
deﬁcient mice, co-cultured 120 h with WT splenic dendritic cells in
the presence of plate-bound CD3 and soluble CD28 plus recombi-
nant TGF-b1 and IL-2.
2.6. Tolerogenic challenge with harmless antigen
To analyze the in vivo function of Treg, we used a previously
described tolerogenic model [14]. Brieﬂy, at day 0, mice were i.t
injected with 800 mg LPS-free OVA (Calbiochem). At day 20, mice
received 3 OVA aerosols (10 mg/mL in PBS, generated using a jet
nebulizer) of 30 min on 3 consecutive days. In some experiments,
10 days later after the i.t administration of OVA, the mice were
immunized with OVA-alum (10 mg OVA adsorbed to 2 mg
aluminum hydroxide) and 10 days later, mice were challenged with
three daily 30-min OVA aerosols as described before.
2.7. Adoptive transfer experiments
Mice were intraperitoneally injected with 10 mg OVA in 2 mg
alum, and 5 days later CD4þ T cells were isolated and expanded
in vitrowith TGF-b and IL-2 in presence of irradiated APC and OVAp.
iTreg cells were intravenously injected (5  106 cells) into Cd69þ/þ
or Cd69/ recipientmice previously intratracheally sensitizedwith
OVA. The recipients were exposed to inhaled OVA (10 mg/mL) for 3
days. For the adoptive transfer experiment with natural Tregs,
CD4þCD25þ-CD69þ or -CD69 Tregs were isolated by FACS sorting
from spleens and 2  105 cells were i.v. transferred to Cd69þ/þ or
Cd69/ recipients.
2.8. Whole-mount staining of mouse tracheas
Tracheas were incubated with PBS containing 0.5% Triton X-100,
5%goat serumandprimaryantibodies [rabbit polyclonal anti-mouse
CD31 (Abcam) and rat clone FJK-16s anti-mouse Foxp3 coupled to
FITC (eBiosciences)]. Samples were washed with 0.3% Triton X-100
in PBS and stained with goat anti-rabbit Rhodamine Red-X (Mo-
lecular Probes). Stained samples were ﬁxed with PFA 4% and
mounted with Prolong® Gold antifade reagent (Molecular Probes,
Life Technologies). Confocal z-stacks from the inner side of tracheas
were obtained using a LSM 700 Laser Scanning Microscope equip-
ped with a LD LCI Plan/Apochromat 25/0.8 Imm Korr DIC M27
(Zeiss). Images were analyzed with Imaris v.7.3.1 (Bitplane).
2.9. In vivo FMT 1500 tomographic imaging and analysis
Mice were injected intravenously with 4 nmol of Neutrophil
Elastase 680 FAST (PerkinElmer, Inc.). OVA-challenged and control
mice were imaged using the FMT 1500 ﬂuorescence tomography
in vivo imaging system (PerkinElmer, Inc.). The collected ﬂuores-
cence data were reconstructed by FMT 2500 system software
version 1.1 for three-dimensional ﬂuorescence quantiﬁcation. The
total amount of lung ﬂuorescence (in picomols) was calculated
relative to internal standards.
2.10. RNA extraction and micro ﬂuidic card analysis
RNA was extracted using Absolutely RNA Nanoprep Kit (Agilent
Technologies). 100e200 ng of total RNA was converted into cDNA
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systems). Relative gene expression was calculated with qbase
software (Biogazelle) using Actb, B2m, Gapdh and Hprt1 as refer-
ence targets genes. Heat map images were generated with Gene
Cluster 3.0 and Java Treeview software.
2.11. Statistical analysis
P values were calculated with the Student t test, and values
below 0.05 were considered signiﬁcant. Means of the experimental
groups were compared by using One-way ANOVA. To account for
multiple comparisons, the Tukey or Bonferroni post-test were used
to compare selected pairs of means and all pairs of means,
respectively. All statistical analyses were carried out with GraphPad
Prism v5.
3. Results
3.1. CD69 is constitutively expressed by a subset of thymic and
peripheral Tregs in steady state
A subpopulation of about ﬁfty percent of total
CD4þCD25þFoxP3þ Treg cells in thymus and secondary lymphoid
organs express CD69 on their membrane in steady state (Fig. 1A).
Further phenotypic analysis of peripheral CD4þFoxP3þ gated
CD69þ and CD69 Tregs from Cd69þ/þ or Cd69/ mice in homeo-
stasis (Fig. 1B), revealed that the suppression-associated markers
CTLA-4, ICOS, CD38 and GITR are expressed at higher levels in
CD69þ-Tregs in steady state compared to CD69 Tregs or Tregs
from Cd69/ mice (Fig. 1C), suggesting that the phenotypic fea-
tures of CD69þ Tregs cells are consistent with an effector Treg
phenotype. However, expression levels of other relevant proteins
for Treg function, such as CD25, CD86 or CD27, are unaffected by
CD69 expression (Supplementary Fig. S1). Interestingly,
CD4þFoxP3þ Tregs homeostasis is not altered in peripheral
lymphoid organs from Cd69/ mice in comparison with Cd69þ/þ
mice (Fig. 1D), indicating that, although Treg development seems
not to be affected by the lack of CD69, their function could be
dampened.
3.2. The suppressive function of Tregs is dependent on CD69
expression
We next assessed the role of CD69 in the suppressive function of
Tregs. Naïve conventional T (Tconv) cells from Cd69þ/þ or Cd69/
mice were co-cultured with CD4þCD25þFoxP3þ Tregs of Cd69þ/þ or
Cd69/ mice and irradiated APCs (iAPCs). Suppressor function of
CD69-deﬁcient Tregs was diminished compared with Tregs from
Cd69þ/þmice (Fig. 2A). This effect was conﬁrmed in the presence of
CD3/CD28 antibodies suppression assays devoid of APCs
(Supplementary Fig. S2). Tregs from Cd69/ mice bearing OTII T-
cell receptors (TCR) speciﬁc for OVA peptide showed almost no
ability to inhibit Tconv proliferation in antigen-speciﬁc suppression
cultures (Fig. 2B).
To conﬁrm those results, we sorted CD69þ and CD69 Tregs
from Cd69þ/þ mice and compared them with the total CD4þCD25þ
Tregs from Cd69/mice (referred hereafter as Cd69/ Tregs) (see
Supplementary Fig. S3A for sorting strategy). All Treg sub-
populations have identical levels of FoxP3þ (Supplementary
Fig. S3B). CD69þ Tregs showed the highest capacity to inhibit the
proliferation of Tconvs, whereas CD69 and Cd69/ Tregs showed
a weaker suppressor function (Fig. 2C). The involvement of CD69 in
Treg function was ascertained in Cd69þ/þ Tregs by addition of the
anti-CD69 monoclonal antibody (2.2), which downregulates CD69
expression [15] and blocks the suppressive function (Fig. 2D). It isworth noting that CD69 expression in untreated CD69þ Treg sub-
populationwas maintained at high levels in vitro after 3 days of co-
culture with Tconv cells (Fig. 2, CeD), indicating that sustained
CD69 expression is critical for the suppressive function of Tregs.We
also analyzed the ability of Tregs differentiated in vitro (iTreg) to
induce effector T cells suppression; although Treg differentiation
process is not compromised in OTII Cd69/ cells (Fig. 2E) or in
Cd69/ cells with normal TCR (Fig. 2G), these cells were unable to
properly induce T cell suppression compared to OT-II-Cd69þ/þ
iTregs (Fig. 2F) or B6 Cd69þ/þ iTregs (Fig. 2H), respectively. These
data indicate that CD69 expression is also required for iTreg sup-
pressive function. To further support these results, we analyzed the
expression of CD69 in Tregs from Foxp3-RFP reported mice. As in
the WT B6 mice, CD69þ and CD69 Tregs maintain the same pro-
portions in lymphoid organs and more importantly, Foxp3-RFPþ
CD69 Tregs showed almost no ability to suppress Tconv prolifer-
ation (Fig. 2I).
3.3. Activation of CD69þ Tregs enhances STAT5 phosphorylation
and decreases ERK phosphorylation
Activation of STAT5 has been reported to be required for Treg
development and suppressive function [16]. To study the molecular
mechanism of suppression by FoxP3þCD69þ Tregs, we stimulated
sorted Tregs and naïve T cells through the TCR and measured the
levels of STAT5, ERK and AKT phosphorylation by FACS. Naïve T cells
from Cd69þ/þ or Cd69/ mice showed no signiﬁcant difference in
STAT5, ERK or AKT phosphorylation (Fig. 3A). However STAT5
phosphorylation in Cd69/ Tregs was inhibited, whereas phospho-
ERK was enhanced at late time points and AKT activation was un-
altered (Fig. 3B). These results are consistent with our previous
results in Th17 cells, where STAT5 activation is partially inhibited in
the absence of CD69 [13]. Addition of IL-2 abolished the differences
in STAT5 phosphorylation between Cd69þ/þ and Cd69/ Tregs
(Fig. 3C), thus indicating that this cytokine restores the activation of
the pathway.
To further study the role of ERK activation in the suppressor
function of Tregs, Tregs isolated from Cd69þ/þ or Cd69/ mice
were treated with the ERK inhibitor U0126. ERK inhibition in Tregs
from Cd69/ mice restored their suppressor activity, whereas it
had no detectable effect in Tregs from Cd69þ/þ mice (Fig. 3D).
Moreover, sorted CD69 Tregs and Cd69/ Tregs partially recov-
ered their suppressor potential after pre-incubation with U0126
(Fig. 3E). To assess whether ERK inhibitors could also restore the
suppressor potential of Cd69/ Tregs in vivo, mice were given
daily i.p. injection with the ERK inhibitor ci 1040 [17]. In vivo in-
hibition of ERK phosphorylation in Cd69/ mice (Supplementary
Fig. S4) restored the suppressor capacity of Tregs isolated from
Cd69/ mice to the level detected for Tregs from Cd69þ/þ mice
(Fig. 3F).
3.4. CD69þ Tregs display speciﬁc cytokine, migratory and Treg cell-
associated gene expression
We analyzed the secretion of TGF-b1 and IL-2, cytokines
involved in the regulation of T cell proliferation. Sorted Tregs were
stimulated with anti-CD3/CD28 mAbs. Cd69/ Tregs secreted
signiﬁcantly less TGF-b1 than Cd69þ/þ Tregs (Fig. 4A). Moreover,
lower levels of soluble TGF-b1 were found in co-cultures of Cd69/
Tregs and Tconvs (Fig. 4B). IL-2 secretion was low in cultures of
Cd69þ/þ and Cd69/ Tregs, consistent with the notion that lack of
IL-2 secretion is a typical feature of mature and functional Tregs
[18] (Fig. 4A). However we observed increased IL-2 secretion in co-
cultures of Cd69/ Tregs and Tconvs (Fig. 4B), which could be a
consequence of the higher proliferation rate of Tconvs in this
Fig. 1. CD69 is constitutively expressed by a subset of peripheral Tregs in steady state. (A) Left, density plots show CD69 expression in gated CD4þFoxP3þ cells in thymus, spleen,
MS-LNs and PLNs from Cd69þ/þmice. Histograms represent CD69 expression on CD4þFoxP3þ cells in Cd69þ/þ (black line) and Cd69/ (red line) mice. Right, the bar chart shows the
percentage of CD69þ and CD69 Tregs within the indicated organs from Cd69þ/þmice ± S.D. (B) FACS analysis of CD4þFoxP3þCD69þ or -CD69 gated spleen cells from Cd69þ/þ and
Cd69/ mice. (C) Cell surface expression of Treg-related markers in CD69þ and CD69 Tregs gated as in (B). Gray-shaded areas represent antibody isotype control and bar charts
show mean ﬂuorescence intensity (MFI) from CD69þ (solid black), CD69 (blue) or Cd69/ (red) Tregs. (D) Cd69þ/þ and Cd69/ mice have comparable proportions of
CD4þCD25þFoxP3þ Treg cells in secondary lymphoid organs. Left panels, ﬂow cytometry analysis of CD4þFoxP3þ cells isolated from spleen, mesenteric (MS-LNs) and peripheral (P-
LNs) lymph nodes of Cd69þ/þ and Cd69/mice of 4, 12 and 20 weeks of age. Right panels, percentage of FoxP3þ on gated CD4þ T cells. Data are representative of three independents
experiments (n ¼ 3 each). Errors bars represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
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and Supplementary Fig. S3B) as well as Foxp3mRNA levels (Fig. 4C)
was the same in CD69þ, CD69 and Cd69/ Tregs or in iTregs from
Cd69þ/þ or Cd69/ mice (Fig. 4D). Thus the functional differences
between CD69þ and CD69 Tregs are unrelated to FoxP3
expression.
To identify differential gene expression patterns we con-
ducted TaqMan immune function gene expression analysis onsorted CD69þ, and CD69 Tregs (Fig. 4 EeG, and Supplementary
Table S1). CD69þ Tregs showed higher expression of cytokine
genes involved in T cell differentiation and function such as Il2,
Il10, Il4 and Ifng (Fig. 4E). Expression of these transcripts was
barely detected in CD69 Tregs. CD69þ Tregs express higher
levels of Cxcl10, Cxcl11 and Ccl5 and chemokine receptors Cxcr3
and Ccr2, involved in the migration of Tregs to inﬂamed tissue
[19]. CD69 Tregs express low levels of most of the receptors and
Fig. 2. Impaired suppressive function of CD69 and Cd69/ Tregs in vitro. (A) In vitro Treg polyclonal suppression assay of CD4þFoxP3þ Treg cells from Cd69þ/þ and Cd69/ mice
and Tconv cells from Cd69þ/þ (left) and Cd69/ (right) mice with coated anti-CD3 Ab in the presence of iAPCs; left panels show [3H]thymidine uptake, and right panels show
percentage of suppression relative to maximum Tconv proliferation in culture without Tregs. (B) FACS analysis of OT-II CD69þ/þ or OT-II CD69/ Tregs suppression function under
antigen-speciﬁc conditions (iAPCs and OVAp). CellViolet show proliferation of Tconvs and bar charts percentage of suppression. (C) Sorted CD69þ and CD69 Tregs from Cd69þ/þ
mice and Cd69/ Tregs were tested in suppression assays with coated anti-CD3 and iAPCs. Left, Percentage suppression of Tconvs. Center, CellViolet shows Tconvs proliferation.
Right, CD69 expression in Tregs co-cultures. (D) In vitro suppression function assay of CD69þ or CD69 Tregs under polyclonal stimulus with or without anti-CD69 2.2 or isotype
control 2.8mAbs. Left, percentage of suppression. Center, Tconv proliferation. Right, CD69 expression in gated Tregs. (E) FACS analysis of in vitro iTreg differentiation cultures of CD4þ
naïve TCs from OT-II Cd69þ/þ or OT-II Cd69/ mice. Bars show the percentage of CD4þFoxp3þ iTregs obtained. (F) iTreg suppression assay of Tconvs cultured with OT-II Cd69þ/þ or
OT-II Cd69/ iTregs. (G) iTreg differentiation cultures with naive CD4þ T cells from B6 WT and CD69/with normal TCR repertoire and cultured together with DCs, anti-CD3/CD28,
TGF-b and IL-2 and (H) iTreg suppression assay of Tconvs cultured with iTregs WT and CD69/ from B6 mice. (I) FACS analysis of splenic CD4þFoxp3þ -CD69þ and -CD69 natural
Tregs from Foxp3-RFP reporter mice (up left). CD4þFoxp3þ -CD69þ and -CD69 nTregs were sorted (up right) and suppression assays of Tconvs were performed. CellViolet show
proliferation of Tconvs and bar charts percentage of suppression (lower panels). Data are representative of three (AeC) or nine (D) independent experiments (n ¼ 3). Errors bars
represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 3. STAT5 and Erk 1/2 activation controls the suppressor potential of Tregs. FACS analysis shows purity and CD69 expression of naïve T cells (A) and Tregs (B) from Cd69þ/þ or
Cd69/mice. Kinetics of STAT5, Erk and Akt phosphorylation after TCR stimulation; gray histograms represent non-stimulated cells and phosphorylation was measured as MFI fold
change. Data are representative of three independent experiments. (C) STAT5 phosphorylation in Tregs stimulated 30 min with IL-2. (D) In vitro suppression assays after pre-
treatment of Tregs with the indicated concentrations of Erk inhibitor U0126 for 2 h. *P < 0.5, **P < 0.01 (comparison of Cd69þ/þ versus Cd69/ Treg), #P < 0.05 (untreated
CD69/ Tregs versus 20 mM U0126 pre-treated CD69/ Tregs). CellViolet indicate Tconv proliferation. (E) In vitro pre-treatment of Tregs with 20 mM U0126 partially restores
suppressor ability of sorted CD69 Tregs and Cd69/ Tregs. Upper histograms, cell violet analysis of Tconv proliferation. Lower, percentage of suppression. (F) In vivo pre-treatment
daily with 100 mg/kg of Erk inhibitor ci1040 (100 mg/kg) or vehicle. Suppressor ability of derived Tregs was tested in vitro. Left, percentage of suppression. Right, Tconv proliferation
in co-culture. Data are representative of at least 3 independent experiments. Errors bars represent mean ± SD. *P < 0.05, **P < 0.01.
J.R. Cortes et al. / Journal of Autoimmunity 55 (2014) 51e6256chemokines analyzed (Fig. 4F). Analysis of surface receptor gene
expression showed that CD69þ and CD69 Tregs express similar
levels of the membrane antigens analyzed (Supplementary
Fig. S5A). CD69þ Tregs expressed high levels of Tbx21 (T-bet),
which together with FoxP3 is important for the suppression of
immune responses in vivo [20] (Supplementary Fig. S5B). Inter-
estingly, expression of Icos and FasL, which are involved in
immune-suppression pathways, was enhanced in CD69þ Tregs
(Fig. 4G). These data indicate that CD69þ Tregs and CD69 Tregs
exist as two independent populations with different pattern of
gene expression.3.5. Tregs from Cd69/ mice have reduced capacity to maintain
immune tolerance and suppress inﬂammation in vivo
We next investigated the tolerogenic potential of Cd69þ/þ and
Cd69/ Tregs in a model of sensitization to inhaled harmless an-
tigens. In this model, primary tolerogenic challenge by intra-
tracheal (i.t.) injection of OVA did not lead to sensitization or lung
inﬂammation upon repeated challenge with aerosolized OVA in
CD69þ/þ mice. However, analysis of bronchoalveolar lavage (BAL)
ﬂuids as previously described [14] showed increased neutrophil
and macrophage inﬁltration in Cd69/mice (Fig. 5A). Detection of
Fig. 4. CD69þ Tregs secrete high amounts of TGF-b and express high levels of immune-suppression related genes. TGF-b and IL-2 secretion by Tregs after TCR stimulation with anti-
CD3/CD28 for 48 h (A) or after co-culture with Tconvs and iAPCs (B) measured by ELISA. Results are representative of three independent experiments. (CeD) Relative Foxp3 mRNA
expression in ex-vivo sorted CD69þ and CD69 Tregs from Cd69þ/þmice, and Cd69 Tregs from Cd69/mice (C) or in vitro differentiated iTregs obtained from OT-II Cd69þ/þ or OT-II
Cd69/ mice (D). (EeG) qPCR analysis of immune-related genes in ex-vivo sorted CD69þ and CD69 Tregs. Heat map represent fold increase to internal standards. Data are means
from three biological samples. Errors bars represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
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Elastase probe administration conﬁrmed that only Cd69/ mice
developed inﬂammation under tolerogenic conditions, indicating
that the absence of CD69 impairs the maintenance of tolerance in
lungs (Fig. 5B). We found higher neutrophil inﬁltration in Me-LNs
from OVA-sensitized Cd69/ mice (Fig. 5C) and this was
conﬁrmed by tomographic imaging (Fig. 5D). Moreover, transgenic
OTKO mice fail to establish lung tolerance, compared to OTII, after
OVA exposure, similar to CD69/ mice in BALB/c background
(Fig. 5E). In a different experiment, after the i.t. tolerogenic chal-
lenge, mice were i.p. immunized with OVA, in order to study the
induction of tolerance after immunization with the same antigen.
After aerosol exposure to OVA mice developed airway inﬂamma-
tion, although the neutrophil inﬁltrationwas signiﬁcantly higher in
Cd69/mice than in Cd69þ/þmice (Fig. 5F). Neutrophil inﬁltration
in lungs and tracheas assessed by tomographic imaging was higher
in OVA-treated Cd69/ mice (Fig. 5G), indicating that CD69
expression is necessary for themaintenance of tolerance in amouse
model of airway inﬂammation.
The lack of CD69 expression on Tregs diminishes the potential to
suppress inﬂammation in response to inhaled antigens (Fig. 5). To
rule out an effect to differences in cell migration capacities ofCd69þ/þ and Cd69/ Tregs after OVA challenge, we analyzed the
content of CD4þFoxP3þ cells in BALS ﬂuid (Fig. 6A) and Me-LNs
(Fig. 6B) ﬁnding no signiﬁcant differences in Tregs cell numbers
between the two genotypes. Analysis of tracheas by whole mount
staining confocal microscopy detected higher numbers of peri-
vascular inﬁltrating neutrophils in Cd69/mice (Fig. 6C); however,
we did not observe any differences in total numbers of FoxP3þ cells
migrating to this tissue, indicating that the migration of FoxP3þ
cells is not affected by CD69 expression (Fig. 6D). Moreover, we
analyzed the expression levels of S1P1 receptor, a molecule
involved in T-cell migration regulated by CD69 expression on the
membrane [4]. We did not ﬁnd any differences in S1P1 receptor
expression levels between Cd69/ and Cd69/ Treg cell subsets
(Supplementary Fig. S6).
3.6. Cd69/ Tregs show impaired function in cell therapy protocols
To demonstrate that CD69 expression on Tregs is required to
restore lung homeostasis and suppress inﬂammation in response to
inhaled antigens, we immunized Cd69þ/þ or Cd69/ mice with
OVA. MS-LNs were collected and cells were ex-vivo expanded with
TGF-b1 and IL-2 in the presence of iAPCs pre-incubated with OVAp.
Fig. 5. Cd69/ Tregs show impaired ability to suppress airway inﬂammation in vivo in a model of lung tolerance. (A) Mice were treated with OVA i.t. 20d before PBS or OVA-
aerosolized challenge. Left, ﬂow cytometry analysis of BALS cells stained with a-CD11b and a-Gr-1, showing the percentage of neutrophils. Right, absolute numbers of neutro-
phils recruited in BALS are shown (B) In vivo detection of activated neutrophils in airways by three-dimensional tomographic imaging in mice treated as in A (left). Right, quan-
tiﬁcation of Neutrophil Elastase 680 probe ﬂuorescence activity. (C) FACS analysis of neutrophils in cell suspensions from Me-LNs. (D) Left, ex vivo tissue imaging of excised Me-LNs
from OVA-challenged Cd69þ/þ and Cd69/ mice. Right, quantiﬁcation of Neutrophil Elastase 680 probe ﬂuorescence activity in the individual lymph nodes excised from different
mice (white boxes). Red bars represent means. (E) OTII and OTKO mice were injected i.t. with endotoxin free OVA previous nebulizations with PBS or OVA and percentage of
neutrophils in BALS were analyzed 24 h after the last exposure to the antigen by FACS. (FeG) Mice were treated with OVA i.t. to induce tolerance and then with OVA i.p. before PBS
or OVA-aerosolized challenge. Detection of neutrophils by tomographic imaging of airways in vivo or in resected lungs and tracheas (lower panels). (G) Neutrophil Elastase 680 probe
ﬂuorescence activity quantiﬁcation. Data are representative of three (AeB) or two (E) independent experiments (n ¼ 5e7). *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 6. Migratory behavior of FoxP3þ cells to the airways and lymph nodes is not affected in CD69/ mice. (A) FACS analysis of CD4þFoxP3þ Tregs in BALS from mice treated with
OVA i.t. before PBS or OVA-aerosolized challenge. Left, numbers indicate the percentage of cells within squares in dot plots. Right, absolute cell numbers of Tregs; red bars indicate
means. (B) Analysis of Tregs in Me-LNs from Cd69þ/þ and Cd69/mice treated as in (A). (CeD)Whole-mount staining with CD31 to visualize vasculature (red) from tracheas of mice
treated as in A. (C) Neutrophil inﬁltration in the trachea analyzed by whole-mount staining as described under methods. Tissues were stained with a rabbit anti-mouse CD31
followed by a goat anti-rabbit Rhodamine Red-X to visualize vasculature (red). In parallel, Neutrophil elastase 680 ﬂuorescent probe was detected with a 633 laser line (bright blue).
Figure shows the three-dimensional isosurface rendering of confocal image stacks. Bars, 30 mm. (D) Whole-mount staining of Foxp3 (Tregs, green) and CD31 (vasculature, red) in
tracheas from PBS or OVA-challenged Cd69þ/þ and Cd69/ mice. Bars, 20 mm. Data are from three independent experiments (n ¼ 6).
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adoptively transferred into recipient Cd69þ/þ or Cd69/ mice on
day 19 of i.t. injection with OVA (see scheme in Fig. 7A). After the
treatment with iTregs, all groups of mice were aerosolized with
OVA three consecutive days 30 min each and i.v. injected with the
neutrophil elastase probe 12 h previous analysis. In vivo imaging
analysis by quantitative tomography indicated that none of the
recipient mice developed features of lung inﬂammation when
challenged with PBS aerosol or transfer of Tregs derived from
Cd69þ/þ donor mice. Interestingly, whereas an inﬂammatory
response was detected in the lungs of Cd69/ recipient mice
treated with Cd69/ donor Tregs, inﬂammation was completely
abolished in Cd69/mice receiving immunotherapy with Cd69þ/þ
Tregs (Fig. 7B and C). In parallel, a different group of mice was
adoptively transferred with 2  105 freshly isolated CD25þ natural
Tregs cells from WT or CD69/ mice, obtained from spleens by
FACS sorting. Percentage of neutrophils in BALS was analyzed 24 h
after the last exposure to PBS or OVA. Conﬁrming the previous
adoptive transfer experiment, the tolerance for OVAwas restored in
CD69/mice treated with CD69 expressing natural Tregs (Fig. 7D).
To rule out a role in Treg migration, we analyzed CD4þFoxp3þ Treg
cells in mediastinal lymph nodes and BALS after adoptive transfer
experiment using nTregs. Although we ﬁnd an increase in Treg
numbers from BALS after OVA exposure, we do not detect any
signiﬁcant differences between WT and CD69/ mice transferred
with CD69þ or CD69 nTreg cells (Supplementary Fig. S7), thus
conﬁrming our previous results pointing to a dysfunction in CD69/
 Tregs rather than a defect in their migration.
4. Discussion
Here we identify a unique CD69-constitutive expressing subset
of Treg cells in homeostatic and inﬂammatory conditions withhigher suppressor potential, than the classical FoxP3þ Treg cell
population as a whole. Consistent with previous evidence that a
subset of thymocytes with high expression of CD69 is the precursor
of human natural Tregs [21], the peripheral subset of CD69þ Treg
differs from CD69 Tregs in the basal expression levels of naturally
occurring Treg markers, such as CD25, CTLA-4, ICOS, CD38 or GITR
[22]. More importantly, FoxP3þCD69þ-Tregs are the more effective
subset suppressing Tconvs; and downregulation of the CD69 re-
ceptor after antibody treatment inhibited their suppressor poten-
tial, indicating that functional suppressor Tregs constitutively
express CD69.
Our data support the notion that the CD69þ Treg cell subset is
the functional suppressive population within the classical
CD4þCD25þFoxP3þ Tregs. However, different subsets of inducible
CD69þ Tregs have also been reported in mice, CD4þCD25FoxP3
Treg precursors, express CD69 on their membrane upon activa-
tion with oral OVA [23], 2,4,6-trinitro-1-chlorobenzene [24] or
after migration within lymphoid organs [25] and tumor induc-
tion [26], and exert their function mainly through membrane-
bound LAP/TGF-b1. Similarly, recent studies in humans have
found the CD69þCD4þFoxP3LAPþ Treg subset in peripheral
blood [27], CD69þCD71þ Tregs after allospeciﬁc activation in vitro
[28], and the diminished suppressive function of Tregs from
systemic sclerosis patients, correlating with lower CD69
expression [29].
FoxP3 has been postulated as a master lineage speciﬁcation
factor for Tregs; however, the data are contradictory, with some
groups postulating that FoxP3þ T cells are a suppressive population
[30] and others describing an incomplete suppressive function in
this population [31e33]. Our data reveal that, within the FoxP3þ
cells, the CD69þ subset is the most potent with suppressive ca-
pacity in vitro and in vivo. Recent data indicate that CD69 associates
with the Jak3/STAT5 pathway, triggering STAT5 phosphorylation
Fig. 7. Cell therapy with Cd69þ/þ Tregs restores lung tolerance in Cd69/ mice. (A) Scheme depicting adoptive transfer with inducible iTregs or natural nTregs obtained from
Cd69þ/þ and Cd69/mice before PBS or OVA-challenge. (B) Detection of activated neutrophils in airways by tomographic imaging. Three-dimensional regions represent neutrophil
elastase activity in upper airways and lung (white boxes) of PBS or OVA-challenged Cd69þ/þ and Cd69/ BALB/c mice treated with ex vivo expanded Cd69þ/þ or Cd69/ iTregs.
Quantiﬁcation of Neutrophil Elastase 680 probe ﬂuorescence activity after treatment with iTregs (C) or nTregs (D). Circles and squares indicate Cd69þ/þ and Cd69/ host mice and
white and black symbols indicate mice treated with exogenous Cd69þ/þ or Cd69/ Tregs, respectively. Data are representative of two independent experiments (n ¼ 4e7). *P < 0.05,
**P < 0.01, ***P < 0.001.
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critical role in Treg development [16]. STAT5 phosphorylation,
which is critical for Treg thymic differentiation, is diminished in
Cd69/ Tregs and lower strength of TCR or costimulatory signals is
required to maintain FoxP3 expression on Tregs, through the in-
hibition of the AKT/mTOR pathway in a TGF-b independent manner
[34,35]. Moreover, inhibition of the ERK MAPK pathway increases
the frequency of FoxP3þ Tregs in a mechanism dependent on TGF-b
signaling [36]. Here we show that, although the AKT pathway and
FoxP3 expression at mRNA or protein levels are not altered in the
absence of CD69 expression in Tregs, the ERK MAPK pathway re-
mains phosphorylated only in CD69/ Treg cells after long term
TCR signaling. Since ERK is not active in CD69þ/þ Tregs, the pre-
treatment of Tregs during 2 h with ERK inhibitor may be effective
only in CD69/ Tregs with activated ERK, having no effect on
CD69þ/þ Tregs with down-regulated ERK signaling. Therefore, in-
hibition of the ERK1/2 pathway in Cd69/ Tregs restores their
suppressive function in vitro and in vivo [37]. Interestingly, the
secretion of TGF-b by CD69-deﬁcient Tregs after TCR stimulation is
signiﬁcantly inhibited, indicating that CD69 exerts its immuno-
regulatory role through the control of the ERK MAPK pathway in
a mechanism dependent on TGF-b.
The regulation of the immune response to aeroantigens is
critical for maintaining immune tolerance in the lungs and pre-
venting airway inﬂammatory disease [38]. In a previous work we
demonstrated that CD69 expression in effector T cells negatively
regulates Th2 and Th17 cell-driven inﬂammatory responsesassociated to allergic asthma and contact dermatitis [39]. How-
ever, the role of CD69 in the function of regulatory T cells and the
maintenance of lung tolerance has not been before explored. Treg
subset is central to the maintenance of mucosal tolerance, and
defects in the development or function of these cells lead to
exacerbated airway inﬂammation typical of allergies and asthma
[14,40,41]. Our studies with a model of lung tolerance show that
Cd69/ Treg cells exhibited a diminished potential to suppress
OVA-speciﬁc inﬂammatory responses, indicating that Treg func-
tion or migration to the lungs was impaired. Adoptive transfer
experiments unequivocally demonstrate that only the
FoxP3þCD69þ Treg subset is able to maintain self tolerance in
Cd69/ mice. However, in vivo analysis of Treg migration to tra-
chea, alveoli and mediastinal lymph nodes indicates an identical
pattern of migration by CD69þ/þ and Cd69/ Tregs. The rate of T
cell migration to the inﬂamed tissue is also regulated by the S1P/
S1P1 pathway, and it has been demonstrated a role of CD69 in the
negative regulation of S1P1 expression levels in T cells [4,42] and
Dendritic cells [43]. In contrast to our previous observations in
CD69/ Th17 cells [39], we have detected any signiﬁcant differ-
ence in S1P1 expression between Cd69þ/þ and Cd69/ Tregs,
suggesting that those are not altered by differential expression of
S1P1. Moreover, S1P1 is an inhibitor of Treg cell function through
AKT-mTOR pathway [44] and we have not found any differences in
this signaling pathway by Cd69þ/þ and Cd69/ Tregs, indicating
that CD69 regulation of Tregs function or migration is indepen-
dent on their expression of S1P1.
J.R. Cortes et al. / Journal of Autoimmunity 55 (2014) 51e62 615. Conclusions
Several mechanisms of suppression by Tregs have been pro-
posed; however, Tregs need to express CD69 to sustain immune
tolerance. Our results thus show that CD69 is a keymolecular target
for controlling Treg-suppressive function and development of
inﬂammation. The identiﬁcation of this new subset of CD69þ Tregs
paves the way toward the development of new strategies of Treg
cell isolation for therapeutic purposes towards chronic inﬂamma-
tory and autoimmune diseases.
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